SCM
Stonepine Capital Management Portfolio holdings
AUM
$102M
This Quarter Return
+7.28%
1 Year Return
+40.04%
3 Year Return
+160.28%
5 Year Return
+195.28%
10 Year Return
–
AUM
$110M
AUM Growth
+$110M
(-13%)
Cap. Flow
-$28M
Cap. Flow
% of AUM
-25.56%
Top 10 Holdings %
Top 10 Hldgs %
87.26%
Holding
31
New
11
Increased
4
Reduced
9
Closed
6
Top Buys
| 1 |
Anika Therapeutics
ANIK
|
$2.65M |
| 2 |
OPTN
OptiNose
OPTN
|
$2.44M |
| 3 |
Galapagos
GLPG
|
$2.26M |
| 4 |
Aclaris Therapeutics
ACRS
|
$2.12M |
| 5 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
$2.12M |
Top Sells
| 1 |
ADMA Biologics
ADMA
|
$17.4M |
| 2 |
Evolus
EOLS
|
$11M |
| 3 |
Rigel Pharmaceuticals
RIGL
|
$6.04M |
| 4 |
Nektar Therapeutics
NKTR
|
$3.25M |
| 5 |
ALIM
Alimera Sciences, Inc.
ALIM
|
$3M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
ADMA Biologics
ADMA
$4.12B
| $20.9M | 19.07% |
1,870,000
-1,556,882
| -45% | -$17.4M |
|
|
ALIM
2
DELISTED
Alimera Sciences, Inc.
ALIM
| $19.5M | 17.81% |
3,511,816
-539,256
| -13% | -$3M |
|
|
3
Evolus
EOLS
$494M
| $18M | 16.41% |
1,657,611
-1,016,745
| -38% | -$11M |
|
|
4
Galapagos
GLPG
$2.07B
| $12M | 10.97% |
485,000
+91,366
| +23% | +$2.26M |
|
|
RVNC
5
DELISTED
Revance Therapeutics, Inc.
RVNC
| $7.2M | 6.57% |
2,800,000
+823,658
| +42% | +$2.12M |
|
6
Xoma
XOMA
$392M
| $5.93M | 5.41% |
250,129
-3,641
| -1% | -$86.3K |
|
|
7
Anika Therapeutics
ANIK
$135M
| $4.19M | 3.82% |
165,397
+104,448
| +171% | +$2.65M |
|
8
TELA Bio
TELA
$70.5M
| $2.94M | 2.68% |
625,645
-62,555
| -9% | -$294K |
|
|
9
Rigel Pharmaceuticals
RIGL
$697M
| $2.51M | 2.29% |
305,000
-735,241
| -71% | -$6.04M |
|
|
OPTN
10
DELISTED
OptiNose
OPTN
| $2.44M | 2.23% |
+2,350,010
| New | +$2.44M |
|
|
11
Aclaris Therapeutics
ACRS
$209M
| $2.12M | 1.93% |
+1,927,446
| New | +$2.12M |
|
12
scPharmaceuticals
SCPH
$295M
| $1.83M | 1.67% |
421,703
-25,073
| -6% | -$109K |
|
13
Aurinia Pharmaceuticals
AUPH
$1.58B
| $1.71M | 1.56% |
+300,000
| New | +$1.71M |
|
14
Milestone Pharmaceuticals
MIST
$156M
| $1.64M | 1.49% |
1,239,199
-223,097
| -15% | -$294K |
|
15
AYTU BioPharma
AYTU
$21.1M
| $1.38M | 1.26% |
472,469
| – | – |
|
16
Kiora Pharmaceuticals
KPRX
$9.55M
| $840K | 0.77% |
+200,000
| New | +$840K |
|
17
Adicet Bio
ACET
$59.9M
| $737K | 0.67% |
609,446
+467,898
| +331% | +$566K |
|
18
Surrozen
SRZN
$104M
| $724K | 0.66% |
+66,084
| New | +$724K |
|
19
Exagen
XGN
$217M
| $653K | 0.6% |
358,697
-25,903
| -7% | -$47.1K |
|
20
Kezar Life Sciences
KZR
$28.9M
| $630K | 0.58% |
+1,050,452
| New | +$630K |
|
21
Aprea Therapeutics
APRE
$9.12M
| $558K | 0.51% |
+137,174
| New | +$558K |
|
|
TSVT
22
DELISTED
2seventy bio
TSVT
| $385K | 0.35% |
+100,000
| New | +$385K |
|
23
Eton Pharmaceutcials
ETON
$464M
| $362K | 0.33% |
+110,000
| New | +$362K |
|
24
Ironwood Pharmaceuticals
IRWD
$214M
| $313K | 0.29% |
+48,012
| New | +$313K |
|
25
Acadia Pharmaceuticals
ACAD
$4.38B
| $81.3K | 0.07% |
+5,000
| New | +$81.3K |
|